ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PBYI / financials
DRUG (46) EVO (47) NGNE (36) STTK (29) ⌘ Pro Terminal →

Puma Biotechnology Inc (PBYI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$10.18 -2.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.16

Puma Biotechnology Inc (PBYI) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (74.5% gross margin, 29% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $538.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PBYI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PBYI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Puma Biotechnology Inc (NASDAQ: PBYI) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $10.18 (-2.49% 1D, market cap $538.9M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 17/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, PBYI ranks #78 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PBYI compare to DRUG and EVO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBYI carries a Roarable B- (70/100 RQD), trailing P/E of 17.5x, gross margin of 74.5%, and ROIC of 29.3%. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $539.9M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PBYI?
▼

Per PBYI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401667), Puma Biotechnology Inc generated $228.4M in revenue (-0.9% YoY), $31.1M in net income, and $41.7M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.16 (-0.21%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 18.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B-
025507510070
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B · Rk C
Cash (14)Whales (13)SEC (9)Macro (17)CEO (17)
Each axis scored 0–20
12M PRICE TARGET CONE+5.4% Base Target
$13 Bull$11 Base$8 Bear
📬 FREE PBYI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBYI)Realized 20D OHLCV Swing Band: ±8.9%
Deterministic 5-Pillar Attribution (70/100 Composite)
🔍 WHY PBYI SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+17/20 pts (24% of score)

FRED Regime × Technicals: 81% of 52W Range • RSI-14 at 52.6 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk9/20 pts (-11 pt drag)

Balance-sheet & 10-K footnote risk deducts 11 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
62
Grade C+$10.12+6.3% Next Q
Q2 (-2Q)
65
Grade C+$10.76+1.5% Next Q
Q3 (-1Q)
67
Grade B-$10.92-6.8% Next Q
Current
70
Grade B-$10.18+6.6% Hist 90D α
Trajectory: C+ (62) → B- (70)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PBYI Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 70/100 (B-) score, PBYI faces multiple-compression risk if 17.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 72.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.87) or 200D SMA ($7.95) invalidates the momentum regime and cuts Target Base ($10.73) toward Bear Floor ($8.35).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBYI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PBYI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 70%NO 30%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PBYI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$41.7M (18.3% FCF Margin)
Revenue$228.4MGross Profit $170.2M (74.5%)Cost of Sales $58.2MOp Profit $37.3M (16.3%)OpEx (R&D/SG&A) $132.9MNet Profit$31.1M (13.6%)Tax/Other $6.2M

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $235.6M
FY24
Rev $230.5M
FY25
Rev $228.4M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$228.4M74.5%16.3%$31.1M$41.7M29.3%
FY 2024$230.5M72.1%13.4%$30.3M$38.9M54.8%
FY 2023$235.6M74.5%13.9%$21.6M$27.0M29.3%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PBYI)

  • ✓Walkthrough of PBYI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PBYI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +35.19%▼ SUPPORT BREAKDOWN
2026-11-03O $10.54H $10.54L $10.18C $10.18VOL 339.6K
RES: $11.80SUP: $10.24SMA50: $9.87SMA200: $7.95
$11.91$10.22$8.52$6.83$5.13RES $11.80SUP $10.24$10.182026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBYI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBYI Butterfly Map → + Track PBYI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
10.5%/yr Implied 5Y Growth

vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PBYI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBYI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PBYI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBYI)

Health Care Rank #78 of 1015 ⚔️ DRUG vs PBYI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBYI vs. DRUG, EVO, NGNE, STTK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Puma Biotechnology Inc (PBYI) ranks #78 by composite RQD confidence (70/100, grade B-) and #429 by equity capitalization ($538.9M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently leads its immediate peer cohort in composite quantitative strength at 70/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PBYI ACTIVE
Puma Biotechnology Inc
B- 70/100 17.5x 74.5% 29.3% -2.49% $538.9M Benchmark Subject
DRUG
Bright Minds Biosciences Inc.
D 46/100 — — — -52.35% $539.9M /drug-vs-pbyi →
EVO
Evotec SE
D 47/100 — — — -0.65% $544.3M /evo-vs-pbyi →
NGNE
Neurogene Inc.
D- 36/100 — — -35.0% -3.41% $551.3M /ngne-vs-pbyi →
STTK
Shattuck Labs Inc.
E 29/100 — — -35.0% -4.32% $558.0M /sttk-vs-pbyi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001401667 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Puma Biotechnology Inc (PBYI) reported GAAP revenue of $228.4M (-0.9% vs. FY2024 revenue of $230.5M , and -3.1% cumulative change since FY2023) , GAAP net income of $31.1M, operating cash flow of $41.8M, and free cash flow of $41.7M (+7.4% YoY). On the balance sheet, PBYI closed FY2025 with $216.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $228.4M $31.1M $41.8M $41.7M $216.3M $0
FY2024 (FY) 2024-12-31 $230.5M $30.3M $38.9M $38.9M $213.3M $21.7M
FY2023 (FY) 2023-12-31 $235.6M $21.6M $27.0M $27.0M — —

3. PBYI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBYI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Puma Biotechnology Inc (NASDAQ: PBYI) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $10.18 (-2.49% 1D, market cap $538.9M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 17/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, PBYI ranks #78 in composite RQD confidence.

How does PBYI compare to DRUG and EVO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBYI carries a Roarable B- (70/100 RQD), trailing P/E of 17.5x, gross margin of 74.5%, and ROIC of 29.3%. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $539.9M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PBYI?

Per PBYI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401667), Puma Biotechnology Inc generated $228.4M in revenue (-0.9% YoY), $31.1M in net income, and $41.7M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PBYI trading relative to its 50-day, 200-day, and 52-week technical levels?

PBYI last traded at $10.18 (-2.49% on volume of 399,317 shares), positioning the stock +3.14% above its 50-day simple moving average ($9.87) and +28.05% above its 200-day simple moving average ($7.95). Across its 52-week range of $4.58 to $11.50, PBYI sits at the 80.9% percentile with a 14-day RSI of 52.6 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($9.27 to $11.09).

Direct Sub-Reports: PBYI RQD Cockpit PBYI 12M Forecast PBYI Earnings & Move PBYI Dividends & DRIP PBYI Insiders & 13F PBYI Whale Options PBYI Profit Sankey PBYI News & Why
ROARABLE RATING BRIEF • RQD 70/100 (B-) ✓ SEC XBRL & RQD VERIFIED

PBYI — Puma Biotechnology Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Puma Biotechnology Inc (PBYI) earns a live Roarable RQD composite score of 70/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $10.18 (-2.49% 1D, market capitalization $538.9M).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 29.3%, gross margin of 74.5%, operating margin of 16.3%, and free cash flow yield of 7.67%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (17/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 8/9, and Debt/Equity of 0.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Puma Biotechnology Inc is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.5B. — for further detail on what the company sells or to whom.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Puma Biotechnology Inc (PBYI) reported $228.4M in annual revenue (up from $230.5M in FY2024, -0.9% YoY) and $31.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($235.6M revenue, $21.6M net income) through FY2025, PBYI scaled operating cash flow to $41.8M and free cash flow to $41.7M, backed by $216.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B- • RQD 70/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 7.67% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $4.58 – $11.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh 17.5x trailing P/E and 13.8x EV/EBITDA against 16.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph records supply_chain as NONE, with empty butterfly_links and proprietary_signals arrays, so upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided sources.

  • Key Question #1: Can PBYI sustain or expand its 16.3% operating margin and 29.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $228.4M and free cash flow of $41.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PBYI's 16.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PBYI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Puma Biotechnology Inc (PBYI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PBYI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PBYI Bull vs. Bear Conversation Board — What's Your Call at $10.18?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PBYI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PBYI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $13.47 (+29.0%)
📌 Pinned Debate

The RQD rating's insider-conviction (17/20) and macro-fit (17/20) pillars, combined with a 29.3% ROIC and 7.67% FCF yield, point to a c

The street is overcomplicating Puma Biotechnology Inc (PBYI). The RQD rating's insider-conviction (17/20) and macro-fit (17/20) pillars, combined with a 29.3% ROIC and 7.67% FCF yield, point to a cash-generative business with institutional accumulation behind it.. With an RQD score of 70/100 (B-) and Forensic Balance Sheet at 9/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $11.28.

EarningsSniper 🐂 BULL

@CreditSpread_Watch Shorting a 13/20 institutional whale-flow stock at $10.44 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $7.93 (-24.0%)
Spot @ $10.44

A 0.2 Altman Z-Score and a 9/20 forensic balance-sheet pillar flag financial-distress risk, and the stock trades near the top of its $4

Sitting on the sidelines or leaning short PBYI above $10.44. A 0.2 Altman Z-Score and a 9/20 forensic balance-sheet pillar flag financial-distress risk, and the stock trades near the top of its $4.58–$11.5 52-week range with reported revenue declining since FY 2023.. Until Fundamental Cash Engine (14/20) and FCF yield (7.67%) inflect higher, upside is capped near $11.50.

LIVE TAPE